Immunochemical Assays and Nucleic-Acid Detection Techniques for Clinical Diagnosis of Prostate Cancer

Prosper Kanyong, Sean Rawlinson, J Davis

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Prostate cancer (PCa) is a significant cause of morbidity and mortality and the most common cancer in men in Europe, North America, and some parts of Africa. The established methods for detecting PCa are normally based on tests using Prostate Specific Antigen (PSA) in blood, Prostate cancer antigen 3 (PCA3) in urine and tissue Alpha-methylacyl-CoA racemase (AMACR) as tumour markers in patient samples. Prior to the introduction of PSA in clinics, prostatic acid phosphatase (PAP) was the most widely used biomarker. An early diagnosis of PCa through the detection of these biomarkers requires the availability of simple, reliable, cost-effective and robust techniques. Immunoassays and nucleic acid detection techniques have experienced unprecedented growth in recent years and seem to be the most promising analytical tools. This growth has been driven in part by the surge in demand for near-patient-testing systems in clinical diagnosis. This article reviews immunochemical assays, and nucleic-acid detection techniques that have been used to clinically diagnose PCa.
LanguageEnglish
Pages523-531
JournalJournal of Cancer
Volume7
Issue number5
DOIs
Publication statusPublished - 10 Feb 2016

Fingerprint

Nucleic Acids
Prostatic Neoplasms
Prostate-Specific Antigen
Biomarkers
Tumor Biomarkers
Growth
North America
Early Detection of Cancer
Immunoassay
Urine
Morbidity
Antigens
Costs and Cost Analysis
Mortality
Neoplasms

Keywords

  • Prostate Cancer
  • Biopsy
  • Immunoassays
  • Clinical Diagnosis
  • PAP
  • PSA

Cite this

@article{1d905517e9314e198bb841decf928eab,
title = "Immunochemical Assays and Nucleic-Acid Detection Techniques for Clinical Diagnosis of Prostate Cancer",
abstract = "Prostate cancer (PCa) is a significant cause of morbidity and mortality and the most common cancer in men in Europe, North America, and some parts of Africa. The established methods for detecting PCa are normally based on tests using Prostate Specific Antigen (PSA) in blood, Prostate cancer antigen 3 (PCA3) in urine and tissue Alpha-methylacyl-CoA racemase (AMACR) as tumour markers in patient samples. Prior to the introduction of PSA in clinics, prostatic acid phosphatase (PAP) was the most widely used biomarker. An early diagnosis of PCa through the detection of these biomarkers requires the availability of simple, reliable, cost-effective and robust techniques. Immunoassays and nucleic acid detection techniques have experienced unprecedented growth in recent years and seem to be the most promising analytical tools. This growth has been driven in part by the surge in demand for near-patient-testing systems in clinical diagnosis. This article reviews immunochemical assays, and nucleic-acid detection techniques that have been used to clinically diagnose PCa.",
keywords = "Prostate Cancer, Biopsy, Immunoassays, Clinical Diagnosis, PAP, PSA",
author = "Prosper Kanyong and Sean Rawlinson and J Davis",
year = "2016",
month = "2",
day = "10",
doi = "10.7150/jca.13821",
language = "English",
volume = "7",
pages = "523--531",
journal = "Journal of Cancer",
issn = "1837-9664",
number = "5",

}

Immunochemical Assays and Nucleic-Acid Detection Techniques for Clinical Diagnosis of Prostate Cancer. / Kanyong, Prosper; Rawlinson, Sean; Davis, J.

In: Journal of Cancer, Vol. 7, No. 5, 10.02.2016, p. 523-531.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Immunochemical Assays and Nucleic-Acid Detection Techniques for Clinical Diagnosis of Prostate Cancer

AU - Kanyong, Prosper

AU - Rawlinson, Sean

AU - Davis, J

PY - 2016/2/10

Y1 - 2016/2/10

N2 - Prostate cancer (PCa) is a significant cause of morbidity and mortality and the most common cancer in men in Europe, North America, and some parts of Africa. The established methods for detecting PCa are normally based on tests using Prostate Specific Antigen (PSA) in blood, Prostate cancer antigen 3 (PCA3) in urine and tissue Alpha-methylacyl-CoA racemase (AMACR) as tumour markers in patient samples. Prior to the introduction of PSA in clinics, prostatic acid phosphatase (PAP) was the most widely used biomarker. An early diagnosis of PCa through the detection of these biomarkers requires the availability of simple, reliable, cost-effective and robust techniques. Immunoassays and nucleic acid detection techniques have experienced unprecedented growth in recent years and seem to be the most promising analytical tools. This growth has been driven in part by the surge in demand for near-patient-testing systems in clinical diagnosis. This article reviews immunochemical assays, and nucleic-acid detection techniques that have been used to clinically diagnose PCa.

AB - Prostate cancer (PCa) is a significant cause of morbidity and mortality and the most common cancer in men in Europe, North America, and some parts of Africa. The established methods for detecting PCa are normally based on tests using Prostate Specific Antigen (PSA) in blood, Prostate cancer antigen 3 (PCA3) in urine and tissue Alpha-methylacyl-CoA racemase (AMACR) as tumour markers in patient samples. Prior to the introduction of PSA in clinics, prostatic acid phosphatase (PAP) was the most widely used biomarker. An early diagnosis of PCa through the detection of these biomarkers requires the availability of simple, reliable, cost-effective and robust techniques. Immunoassays and nucleic acid detection techniques have experienced unprecedented growth in recent years and seem to be the most promising analytical tools. This growth has been driven in part by the surge in demand for near-patient-testing systems in clinical diagnosis. This article reviews immunochemical assays, and nucleic-acid detection techniques that have been used to clinically diagnose PCa.

KW - Prostate Cancer

KW - Biopsy

KW - Immunoassays

KW - Clinical Diagnosis

KW - PAP

KW - PSA

U2 - 10.7150/jca.13821

DO - 10.7150/jca.13821

M3 - Article

VL - 7

SP - 523

EP - 531

JO - Journal of Cancer

T2 - Journal of Cancer

JF - Journal of Cancer

SN - 1837-9664

IS - 5

ER -